our joining thanks Thank to you, call everyone this Dan. And afternoon.
slide Let's on X. start
We year. with drivers progress creating value. made the long-term on to in exited quarter focused we year, the the team Last groundwork pleased continued fourth we operational sustainable the are the key on and how lay
start me April SIVEXTRO of in with our Let the own for XXXX. NDC launch
this which allowed sales provided impact of to a As XXX% P&L. net you product to for us recognize has recall, our SIVEXTRO, positive
for of We quarter sequential continue ongoing are to another see and to momentum prescription happy growth. report SIVEXTRO
China already in development anti-infective their to of in opted complement Greater transitioned we the Greater to to in pursue and Next, China product space commercialization existing region, China rights putting lefamulin them Sumitomo in forward position anti-infective providing player in the Pharmaceuticals. November regulatory a lefamulin dominant Sumitomo that been is the portfolio lefamulin the China. for accepted Greater Sumitomo to when available. approved. updates launch we once in announced has to by NDA a authorities, and solid lefamulin look We in
As we as net of on double-digit achievement payments of the sales milestones. a reminder, are up sales, royalties $XX well entitled upon to low regulatory certain million and to as
the approval of is milestone first The upon in which due region.
from months this authorities mentioned, November be drug in the when within accepted application XX previously XX we'd expect new to to the As approval regulatory XXXX.
second Moving our to product, XENLETA. commercial
broaden we We and and in November allows accessible further the XX-count channels. more pack patients making the for retail X continue progress launched for which last in US. the availability improved Pack, make opportunity to convenient of access to in In oral year, product or the patient
support opportunity could given for community-acquired care a a and its formulations. We affords good pneumonia. to XENLETA antibiotic IV visibility the hospitals. pharmacy Next, we of This agreement of through the partnered formulation be awareness this of with their hospital an oral alternative IV XENLETA transition alternative XENLETA for as as treatment XENLETA by network Vizient Vizient's in systems expand increasing network option of believe of
explore We continue advanced of additional Fibrosis and XENLETA uses Cystic to the program. have
month. the I XXXX. good dosed are trial the anticipate and are next within expected the first patient We in CF safety progress and Phase The making with PK data
on very strains in and CF applications program The the Fibrosis patients. activity Our peer-reviewed potent of Cystic anti-inflammatory potent in is isolated optimism and vitro we encouraging in XENLETA infections, vivo from particular. journal against potential patient One, population potent of lefamulin and aureus lefamulin in the wide-ranging demonstrating based anti-inflammatory the staph In data various CAP CF. models. properties in The antimicrobial of has anti-inflammatory aspects anti-staphylococcal published combination PLOS properties to lefamulin for of including has is this for a October,
with continue These to debt Hercules. amended from negotiations financial with for agreements, performance manufacturer third-party position strong Lastly, Hovione, strengthen fourth XENLETA we well the extended with agreement our along quarter into runway with contracts our our our on of cash our SIVEXTRO XXXX. and
to Moving slide X.
enhance December roughly patients have million ahead multiple date, have we franchises. XXXX, the our cash of are XX, can and company. more $XX shareholder to for importantly, drivers near of we We value believe each we XXXX. key on the accomplishments significant over extended with the our fourth now as of term lie into maximize We that but runway excited core hand see benefit what the that as catalysts With well quarter cash with we value the as of
to cash our by our further progress show based our portion This sales and which commercial levels US. costs, mid-XXXX. continues SIVEXTRO a funding in G&A SIVEXTRO confidence efforts historical peak us that solid reach strategy guidance helping will is gives our overall sales burn. the to growth on of reduce Our Fully to foundation, the strong reaffirm while
care ways for and are patients access for optimize practitioners. seeking we health continually to As XENLETA,
of for have important for large antibiotic see product we Board in in patients X before, proposition Advisory the a giving an us with patent health adult It's approximately setting. XXXX, Board recently who and potential with have the Advisory an and interaction and time to in pulmonologists extensive patients understand value the assess create like held value until XENLETA. significant million market care value said As runway the out and we CAP we continue the practitioners. XENLETA is outpatient market. as a raise with provided XENLETA awareness We insights The that remember to evaluate for to positive
opportunities could we small million determine to Additional if we translate potentially generate Fibrosis, the XENLETA which The Cystic investment a include major for believe estimated catalyst the incremental $XXX data I non-clinical for be so, is company. this potential sales. a of clinically, and in Phase trial could if
partnership States. This additional with provide we United XENLETA, with continue has the potential funding. to the company outside Lastly, to opportunities explore which another resource, the is non-dilutive
partnerships are regions, other including and negotiating actively existing in We China and in Europe. have Canada
committed patients CONTEPO we market. MDR large suspected unmet States remain for are or or on, infections the by An multi-drug-resistant United to confirmed the MDR. X Moving for treated treating a is United We still to States estimated million in caused with in bring organisms. the believe people there need
another we Turning growth saw than X. SIVEXTRO and more sequential slide TRx's. to quarter X,XXX straight quarter posted of where SIVEXTRO the second
In for now to has commercially sales grow drive coverage. SIVEXTRO are a team, XENLETA's with of earlier patient and experienced continue slide infrastructure utilization our established this with sales. to like the We shown the for differentiated historical established, our executing its addition an we we which see reinforced commercial organization the back With peak the well and capability to positive demonstrating SIVEXTRO. towards access brands potential pulmonologists ability to positioning. board Shifting X, held lot year, XENLETA and with novel product characteristics on advisory broad mechanism to
community. and CAP IV options. formulations oral of the the need The for availability ongoing of of hospital for One to main treatment the efficient transition takeaways from was allows care
availability importantly, Advisory an course Board from allow anti-inflammatory of potent is to of the also treatment the hospitalizations. help in positive therapy attribute. another for short supports X-day interest the avoid XENLETA. properties option More the community may oral Feedback The in of
expanded from to and We is continue a about prevalent publication continue was its staggering empiric the of community-based and of providers common. and deaths more attributable be as on CONTEPO with perspective, recent Switching estimated by HCPs, interactions resistance X.XX from important that about as as million AMR more silent the outcomes or deaths to Based the to they CONTEPO drug to to malaria that especially such were Cystic ongoing more explore optimism attributed antimicrobial slide it utility areas be for put prospects first-line to XENLETA AMR a Lancet, annual pandemic view in agent. reality for outnumber into that in in we globally. deaths XENLETA globally. This XXXX insights bolstered how the usage continue learn breast our is a now XX, the To cancer HIV, Fibrosis. patient plan from negative to on gaining a becoming framework
Klebsiella pneumonia, aeruginosa. pathogens pneumonia, just million for or and pathogens Importantly, under E. followed resistance baumannii coli attributable by for aureus, associated deaths And the with staph AMR. to leading deaths pseudomonas Acinetobacter these accounted X six streptococcus
has likely Klebsiella pivotal of commonly and against CONTEPO in well been has against in mechanism most coli tolerated vitro highly resistant shown several pyelonephritis. of active be are pneumonia CONTEPO to aware, be effective a UTI pathogens. action been trial you these As novel demonstrated has E. to and that for our complicated
United indications States multiple outside extensively fosfomycin years In the approved addition, is for used and many IV for now.
States. option confirmed are infections unique and result, benefits, CONTEPO multi-drug-resistant for suspected with aware as United of opportunity in believe a already a physicians there for the or many treatment potential is potential As US the we drug's a patients
part the for Chief For I'd Officer, Steve? the the over our the Dr. Operating to brief and of presentation, update it status a of next Gelone, turn to NDA. CONTEPO like President Steve on
